Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Natural Killer Pnk Cells Equipment Supplied In Europe
23 equipment items found
by:BlueSky Immunotherapies GmbH based inWien, AUSTRIA
The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor derived) CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed by a broad range of tumor cells and the novel inhibitory peptide TIM (TCR Inhibitory Molecule). The expression ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
ENKASTIM is based on the activation of immune cells called natural killer (NK) cells that are major players in the body's first line of defense, also called innate immunity. The immune effector cells are activated ex vivo (outside the body; ENKASTIM-ev) or in vivo (inside the body; ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
In vivo application of ENKASTIM-iv, an Hsp70-based GMP-grade synthetic peptide comprising 14 amino acids (14mer), results in a specific activation of NK cells which acquire the capacity to recognise and kill membrane Hsp70-positive tumors and ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
The proprietary ROCK platform enables a tumor-targeted approach that can be tailored across hematological and solid tumors. The ROCK (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE (innate cell engager) molecules. High-affinity ICE (innate cell engager) molecules, which are created using the ROCK platform, are capable of bivalent NK-cell ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA ...
Manufactured by:Sartorius CellGenix GmbH based inFreiburg, GERMANY
CellGenix Recombinant Human GM-CSF reliably supports the differentiation of CD14+ monocytes into mature dendritic cells (DCs). It is produced in our dedicated animal-free facility ensuring maximum safety for optimal use in ATMP ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
Manufactured by:Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH based inReutlingen, GERMANY
Coxsackievirus B3 (CVB3) of the enteroviruses of the family Picornaviridae is associated with a variety of acute and chronic forms of diseases including meningoencephalitis, insulin-dependent type I diabetes (IDDM) (Curr Diab Rep. 2010;10(5):350-6) and, importantly myocarditis (Eur Heart J. 2013;34(33):2636-48). Although most enterovirus infections are subclinical, these viruses are capable of ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:OncoVITA based inParis, FRANCE
Oncovita’s MeasovirTM proprietary platform relies on a DNA plasmid vector that expresses a modified measles Schwarz virus antigenome able to generate recombinant viruses by using a clonal reverse genetics system. This versatile plug-and-play platform allows producing new viruses expressing very large amounts of additional genetic ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous involvement (44% ORR).5 When used in combination with allogeneic ...
Manufactured by:Precision For Medicine, Inc. based inFrederick, MARYLAND (USA)
PBMCs are a vital component to understanding human immune function and disease response. Variability in quality, availability, and purity can derail a research study. At Precision for Medicine, PBMCs are collected and processed within our FDA-registered facility to ensure optimal cell yields, viability, and quality. ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
The company´s proprietary platform technology is based on the discovery of a novel tumor-specific marker - a membrane-expressed form of heat shock protein 70 (Hsp70). Membrane Hsp70 is most frequently expressed on a variety of different tumor types including lung, colon, breast, head and neck, stomach, pancreas carcinomas, malignant melanoma, and hematological diseases, but never on the ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. LAVA-051 uniquely activates both Vγ9Vδ2 T cells as ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. Potential to treat various solid tumor types with a more acceptable safety profile while remaining immune to the challenge of ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...
Manufactured by:Minaris Regenerative Medicine, LLC based inAllendale, NEW JERSEY (USA)
At Minaris Regenerative Medicine, we are committed to bringing together and further developing highly talented, skilled, and dedicated experts with varied backgrounds applicable to gene and cell therapy manufacturing and development. Having this team creates the potential to accelerate your progress to market and to both anticipate and overcome your challenges, while reducing the overall cost and ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
ENKASTIM-ev is an innovative product candidate representing a new class of therapy known as Active Cellular Immunotherapies (ACIs). ACI is a treatment approach which capitalizes on the power of vital human cells to re-engage the patient's own immune system to fight cancer. The product induces a targeted immune response against surface-bound heat shock protein 70 (Hsp70). Surface-bound Hsp70 is a ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases.1 Today, we ...